Physician profile
Esmat A Gayed
NPI 1811007651
$691.05
in general payments reported to CMS, 2019-2025
12 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.74 · 2020: $15.63 · 2023: $256 · 2024: $117 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $138.13 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $132.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $83.54 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.11 | 2024-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $58.03 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $51.96 | 2019-2023 | Arexvy, Shingrix |
| Dexcom, INC. | $42.66 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $41.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.56 | 2023-2024 | Farxiga, Breztri |
| Amgen INC. | $18.29 | 2025 | Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $16.66 | 2019 | |
| Astellas Pharma US INC | $13.97 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esmat Gayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.